James P Thomas, MD, PhD - Chairman, Chief Executive Officer: Dr. Thomas received his PhD in biochemistry in 1989 and his MD from the Medical College of Wisconsin in 1991. His doctoral thesis was on reactive oxygen species and cancer treatment. Dr. Thomas completed an internal medicine residency while simultaneously performing a postdoctoral research fellowship in biophysics, studying free radical biochemistry. He then went on to complete a medical oncology fellowship and joined the medical oncology faculty at the University of Wisconsin in 1998. Dr. Thomas was an Associate Professor at the Ohio State University Comprehensive Cancer Center from 2005-2010 where he directed clinical trial activity and 65 research staff for the cancer center. Dr. Thomas is currently a Professor of Medicine in the hematology/oncology division at the Medical College of Wisconsin as well as a part of the medical staff of Froedtert Hospital, a major teaching affiliate of the College. Dr. Thomas clinical research interests are in early phase drug development and he has led the phase I trials for a number of first in man studies. Dr. Thomas has published over 70 scientific articles in the areas of reactive oxygen species and cancer drug development.
Dr. Thomas is a member of numerous professional organizations and is the current chair of the Association of American Cancer Institute's Clinical Research Initiative. He is an ad hoc manuscript reviewer for major journals including Lancet, Oncology, Annals of Surgery and Cancer Chemotherapy and Pharmacology and has served as an external reviewer of the NCI Medical Branch.
Kristine K Hahn, PharmD - Senior Research Scientist: Kristine received her PharmD degree in 2004 from the University of Wisconsin-Madison School of Pharmacy. She went on to complete 3 years of postdoctoral training at the University of Wisconsin Comprehensive Cancer Center. During her training, she focused on genetic biomarkers as tools for determining cancer susceptibility and predicting drug response and toxicity. Kristine joined Perscitus Biosciences in the summer of 2007.